San Diego, CA. USA (UroToday.com) – 11Choline-acetate (11C-acetate) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated transports in prostate cancers after prostatectomy to detect recurrence and metastasis upon biochemical relapse. Its utility for predicting outcomes in this group of patients has not been reported. Naresh Kumar Regula, from the Uppsala University, Sweden presented new data at the 2016 Society of Nuclear Medicine and Molecular Imaging annual meeting. The question of whether parameters measured by 11C-acetate PET correlate with clinical outcomes including survival.